CINOBAC
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 31m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CINOBAC is an oral small-molecule antibiotic capsule approved in 1980 by Eli Lilly. The specific indication and mechanism of action are not available in current data, limiting definitive characterization. This legacy product represents a mature segment of the antibiotic market with limited growth potential.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), this product is in defensive posture; team focus is likely on margin protection and gradual transition planning rather than market expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, CINOBAC represents a consolidation or wind-down assignment rather than a growth opportunity. Career professionals should expect a focus on profitable volume retention, channel management, and organizational restructuring rather than market expansion or innovation.
Brand ManagerSales Representative
Worked on CINOBAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.